Tilt also reported a net loss of $12.6 million in the quarter versus a net loss of $8.7 million in the prior year period. At ...
Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback